Table 3.

Laboratory measures of coagulation after attempted reversal

	Dabigatran	Rivaroxaban	Apixaban	P values
Patients reversed (n)	7	31	6
Best INR (IQR)*	1.3 (1.2–1.4)	1.2 (1.1–1.3)	1.1 (1–1.2)	0.0096
Best aPTT (IQR)†	34 (29.8–44.6)	30.1 (26.9–24.5)	29.2 (26.1–33.2)	0.0014
Best TEG R median (IQR)‡	5.2 (3.9–6.9)	5.4 (4.3–7.3)	4.2 (2.4–5)	0.2125
Best TEG alpha median (IQR)‡	70 (67.8–73.6)	71.2 (65.6–77.4)	71.2 (63–77)	0.8723
Best TEG MA median (IQR)‡	66.8 (61.5–70.1)	67.1 (62.4–72.5)	65.3 (56.7–69.8)	0.9364

Significant values in bold. Normal values: PT=9.7–12.5; aPTT=25–34; R=5–10; alpha=53–72; MA=50–70; lysis=0%–8%.

*Repeat INR performed after reversal in 6 dabigatran, 27 rivaroxaban, and 4 apixaban patients.

†Repeat aPTT performed after reversal in 6 dabigatran, 24 rivaroxaban, and 3 apixaban patients.

‡Repeat TEG performed after reversal in 3 dabigatran, 11 rivaroxaban, and 2 apixaban patients.

INR, international normalized ratio; MA, maximum amplitude; PT, prothrombin time; TEG, thromboelastography; aPTT, activated partial thromboplastin time.